

The background of the slide features a grayscale image of an antibody molecule, which is a complex, Y-shaped protein structure. Overlaid on this are several white, five-pointed stars arranged in a circular pattern, reminiscent of the European Union flag. The text is positioned in the lower-left quadrant of the image.

FCF Fox Corporate Finance | FCF Life Sciences
Life Sciences Venture Capital Monitor – Europe


May 2023

Antibody



THE FINANCING SPECIALIST

**FCF LIFE SCIENCES
OVERVIEW**



Overview



Focus on Biotech, MedTech and HealthTech

We advise innovative companies on arranging, structuring and placing equity, debt, and licensing transactions in a holistic financing approach



Focus Areas

FCF advises on the following transaction types:



FCF Life Sciences
advises leading Life Sciences companies in Europe in financing transactions

Over **EUR 2bn** Life Sciences transaction volume
(Professionals and Advisors)

Life Sciences Team of **>12**

Over **100** years in aggregated Life Sciences experience

Access to **> 1,500** international investors

Company Valuation
in partnership with **BioScience Valuation GmbH**

China Licensing
in partnership with **YAFO Capital**

Leading EIB advisor in Europe

Over **80** completed Life Sciences transactions
(Professionals and Advisors)

8 regularly published Life Sciences reports

Life Sciences Team



Dr. Alexandra Goll
Advisor – Venture Capital



Dr. Axel Polack
Advisor – Science & Technology



Claus Schalper
Advisor – Corporate Affairs



Mathias Klozenbuecher
Head of Life Sciences



Johannes Link
Life Sciences Banking – Europe



Marcel Christou
Life Sciences Banking – Europe



Enno Spillner
Advisor – Capital Markets



Dr. Joachim M. Greuel
Advisor – Valuations



Prof. Dr. Horst Domdey
Advisor – Science & Technology



Zaid Maleh
Life Sciences Banking – Dubai



Sean Jian, CFA
Life Sciences Banking – China



Services

- ✓ Integrated Financial Modelling
- ✓ Investor Screening
- ✓ Management Presentation
- ✓ Post-Transaction Support
- ✓ Due Diligence Support
- ✓ Financing Strategy Advisory
- ✓ Investor / IR Roadshow
- ✓ Equity & Debt Fundraising
- ✓ Term Sheet Negotiation
- ✓ Life Science Advisory Board
- ✓ Closing Assistance
- ✓ IPO Execution Support

(extract from service portfolio)

Our capital markets research feeds our proprietary investor database

Data Collection

Life Sciences Venture Capital Monitor – Europe



- Venture Capital
- Life Sciences*
- Focus on Europe

Biotech Venture Capital Monitor – US



- Venture Capital
- Life Sciences
- Focus on the US

Life Sciences Venture Capital Report



- Venture Capital
- Life Sciences
- Focus on Europe and the US

Biotech Licensing Monitor – China



- Licensing
- Biotech
- Focus on Europe and Chinese licensors

Biotech Public Equity Monitor



- Public Equity
- Biotech
- Focus on Europe

MedTech Public Equity Monitor



- Public Equity
- MedTech
- Focus on Europe

Life Sciences IPO Report



- IPOs
- Life Sciences
- Focus on Europe and the US

Life Sciences SPAC Monitor



- SPACs
- Life Sciences
- Focus on US / Europe and US SPACs


Market Monitoring

Data Processing

- Transaction data
- Investment preferences

Proprietary Investor Database

- Most comprehensive database
- > 1,300,000 data points



Constant Data Enrichment

- Ongoing investor communication
- Data validation

Data-driven Investor Selection

1
2
3

- Intelligent search algorithms
- Big data sequencing

Executive Summary

The FCF Life Sciences Venture Capital Monitor - Europe is a monthly published overview focusing on the venture capital financing environment in the Biotech, Pharmaceutical, MedTech and HealthTech segments, and can be used as a quick reference for investors, corporates and professionals

More advanced, detailed and / or customized reports are available upon request

FCF Life Sciences Venture Capital Monitor - Europe

is a monthly published overview of Biotech, Pharmaceutical, MedTech and HealthTech companies, displaying venture capital financing trends in the European life science industry

Scope

The selection of companies is based on the following criteria:

- Focus on transactions with European headquartered life science companies and available deal volume
- Companies operating in the Biotech, Pharmaceutical, MedTech, HealthTech, Services or other life science related sectors
- The Biotech sector is further divided into the following therapy areas / indications: Cardiovascular, Central Nervous System, Dermatology, Ear Nose Throat Disorders, Gastrointestinal, Genetic Disorders, Genito Urinary System And Sex Hormones, Hematological Disorders, Hormonal Disorders, Immunology, Infectious Disease, Male Health, Metabolic Disorders, Mouth and Dental Disorders, Musculoskeletal, Non Malignant Disorders, Nutritional Disorders, Oncology, Ophthalmology, Respiratory, Toxicology, Women's Health

To recommend colleagues or fellow investors to be added to the mailing list, kindly send an email with the respective contact information

Recipients

The FCF Life Sciences Venture Capital Monitor - Europe targets the following recipients:

- Corporates / Executives
- Institutional investors
- Private equity investors
- Venture capital investors
- Family Offices / High-net-worth individuals
- Advisors

Availability

The FCF Life Sciences Venture Capital Monitor - Europe is available on FCF's website at "<https://www-fcf-de/de/life-sciences/>"

Data

All input data is provided by Pitchbook or GlobalData and is not independently verified by FCF- Ratio and multiple calculations are driven based on the input data available- For additional information and disclaimer, please refer to the last page

If you have questions, comments or ideas, please do not hesitate to contact us


**EUROPEAN VENTURE CAPITAL
TRANSACTIONS IN LIFE SCIENCES**

MAY 2023




Overview (YTD)


Cumulative Financing Volume (EURm)




Subsectors




Indications¹



Top Company Origins



Top Investor Origins



Top 5 Deals

#	Company	HQ	Deal Volume	Series
1	YgEia3	UK	683	E
2	Distalmotion	CH	138	F
3	Amolyt Pharma	FR	130	C
4	Hemab Therapeutics	DK	125	B
5	Ascend Gene And Cell Therapies	UK	120	A

Top 5 Investors

#	Investor	HQ	Deal Volume ²	# of Deals
1	Revival Healthcare Capital	US	138	1
2	Gilde Healthcare Partners	DK	70	5
3	European Innovation Council Fund	DE	68	16
4	Novo Holdings	DK	64	5
5	Jeito	DK	61	4

#	Date	Company	HQ	Subsector	Vertical - Indication / Stage	Company Description	Deal Series	Deal Volume (EURm)	Total Raised (EURm)	Deal Synopsis
1	31-05-2023	Anocca	SWE	Biotech / Pharma	Oncology / Pre-clinic	Developer of drugs and immunotherapies intended to unlock the therapeutic potential of T-cell immunity.	D	35	146	The company raised SEK 400 million of venture funding on May 31, 2023. The funds will be used to further develop its unique process that enables the discovery and manufacture of cell therapies for cancer on an industrial scale and to progress its first products into clinical trials
2	31-05-2023	Hedepy	CZE	Healthcare Services	Mental Health Services / On market	Developer of an online videoconference therapy platform designed to help individuals with various presenting problems.	B	2	4	The company raised EUR 2.15 million of venture funding on May 31, 2023. The funds will be used for the company's ongoing expansion into four other countries, but also for the development of online psychiatric care, which it is currently working on.
3	30-05-2023	Inbentus	ESP	MedTech	Mechanical Ventilation / On market	Developer of high medical equipment designed for mechanical ventilation and other medical devices.	A	2	3	The company raised EUR 2 million of venture funding on May 30, 2023. The funds will be used to accelerate its growth and expand its research and development capacity for new equipment and technologies related to mechanical ventilation and resources will be allocated to the international expansion of the company, consolidating its position as a leader in innovative medical solutions.
4	30-05-2023	Japet	FRA	MedTech	Robotic Exoskeleton / On market	Developer of wearable robotic exoskeletons designed for occupational and daily health.	B	1	4	The company raised EUR 1.2 million of equity crowdfunding on May 30, 2023.
5	29-05-2023	Encare	SWE	HealthTech	Medical Application / On Market	Developer of an interactive and web-based information system designed to help surgical teams implement the perioperative care process.	B	2	6	The company raised EUR 1.5 million of venture funding on May 29, 2023. The funds will be used to further increase revenue by expanding sales to existing customers and acquiring new customers as well as to prioritize product development to cater to specific market needs.
6	26-05-2023	AGADE	ITA	MedTech	Smart Exoskeleton / Undisclosed	Developer of a smart exoskeleton designed to reduce operator fatigue in the actions performed by the upper limbs.	B	4	11	The company raised EUR 4 million of venture funding on May 26, 2023.
7	25-05-2023	VarmX	NLD	Biotech / Pharma	Hematology / Developing	Developer of therapeutic drugs intended to restore blood clotting in bleeding patients.	2	30	75	The company raised EUR 30 million of Series B2 venture funding on May 25, 2023. The funds will be used to obtain investigational new drug (IND) approval for its lead compound VMX-C001 and to complete preparations for the pivotal clinical trial, including large scale manufacturing.
8	25-05-2023	Manus Neurodynamica	GBR	MedTech	Neuroscience Device / On market	Developer of neuroscience device designed to diagnose and monitor biomarkers in neuromotor impairments.	C	3	6	The company raised GBP 2.62 million of venture funding on May 25, 2023, putting the company's pre-money valuation at GBP 3.06 million. The funds will be used to allow the company to continue its launch into the EU pharmacy retail sector, focused on prevention screening, and global clinical markets, as well as support the company's application for US FDA regulatory clearance and progress its US trials, as well as further developing and implementing its US commercialization strategy.


Source: PitchBook as of 02-06-2023; FCF Equity Research

Note: All volumes in EURm; financing rounds without deal values are excluded


¹Only includes biotechnology and pharmaceutical deals; ²Proportional attribution of deal values to investors participating in a transaction (transaction volume / # investors by financing round)

Overview (YTD)


Cumulative Financing Volume (EURm)




Subsectors




Indications¹



Top Company Origins



Top Investor Origins



Top 5 Deals

#	Company	HQ	Deal Volume	Series
1	YgEia3	UK	683	E
2	Distalmotion	Switzerland	138	F
3	Amolyt Pharma	France	130	C
4	Hemab Therapeutics	Denmark	125	B
5	Ascend Gene And Cell Therapies	UK	120	A


Top 5 Investors

#	Investor	HQ	Deal Volume ²	# of Deals
1	Revival Healthcare Capital	USA	138	1
2	Gilde Healthcare Partners	Denmark	70	5
3	European Innovation Council Fund	Germany	68	16
4	Novo Holdings	Denmark	64	5
5	Jeito	Denmark	61	4


#	Date	Company	HQ	Subsector	Vertical - Indication / Stage	Company Description	Deal Series	Deal Volume (EURm)	Total Raised (EURm)	Deal Synopsis
9	25-05-2023	Mysphera	ESP	HealthTech	Health Management Software / On market	Developer of a health process management software designed to transform healthcare systems through location and process visibility.	D	3	14	The company raised EUR 2.7 million of venture funding on May 25, 2023. The funds will be used to strengthen the company's global expansion and become a leader in the Real Time Location Systems (RTLS) market, one of the possible solutions to waiting list problems in the healthcare sector.
10	24-05-2023	InProTher	DNK	Biotech / Pharma	Oncology / Pre-clinic	Operator of a biotechnology company intended to treat cancer by targeting tumor viruses within the human genome.	A	6	1	The company raised EUR 6 million through a combination of convertible loan and equity on May 24, 2023. The funds will be used to advance its lead drug candidate, IPT001, a first-in-class immunotherapy against solid tumors, into clinical development.
11	24-05-2023	Eyr	NOR	HealthTech	Digital Healthcare Platform / On market	Developer of a digital healthcare platform designed to connect patients with doctors through video consultations.	D	2	48	The company raised NOK 22 million of venture funding on May 24, 2023.
12	24-05-2023	CaSRvolution	ITA	Biotech / Pharma	Central Nervous System / Undisclosed	Operator of a medical research platform intended for devising therapies for neurodegeneration diseases.	A	2	2	The company raised EUR 1.8 million of venture funding on May 24, 2023. The funds will be used to intensify its Drug Discovery activities by exploiting a completely new mechanism of action upstream of the typical clinical manifestations of the disease, with the aim to identify a clinical candidate that could arrest neurodegeneration in Alzheimer's patients.
13	24-05-2023	Gedea Biotech	SWE	Biotech / Pharma	Women's Health / Developing	Developer of an antibiotic-free treatment intended to treat and prevent vaginal bacterial and fungal infections.	C	1	2	The company raised EUR 1.3 million of venture funding on May 24, 2023. The funds will be used to continue the ongoing proof-of-concept study for the treatment of Vulvo Vaginal Candidiasis (VVC) with pHyph, investigating how the vaginal microbiome changes during short- and long-term treatment with pHyph in patients with bacterial vaginosis and preparation of an additional clinical study for the treatment of bacterial vaginosis, planned to start after the summer.
14	24-05-2023	Birdt Health	NLD	HealthTech	Health Platform / On market	Operator of an online booking platform intended to connect users with psychologists to treat mental health issues.	A	< 1	< 1	The company raised EUR 250,000 of venture funding on May 24, 2023. The funds will be used for the development of an innovative mental health care method based on the network model.
15	23-05-2023	TISSIUM	FRA	Biotech / Pharma	Dermatology / Developing	Developer of biodegradable sealants and adhesives for surgical-wound closure designed to address various unmet clinical needs.	D	50	178	The company raised EUR 50 million of Series D venture funding on May 23, 2023, putting the company's pre-money valuation at EUR 190.38 million. The funds will be used to continue to execute the development plan, funding the company for the commercialization of its first products in nerve and hernia repair and fueling the extension of its pipeline of products and its platform.
16	23-05-2023	CARE (Monitoring Equipment)	CHE	HealthTech	Preventive Care Application / Undisclosed	Developer of a preventive care application designed to track blood values and monitor digitized health.	-	5	8	The company raised \$6 million of angel funding in May 2023.

Overview (YTD)


Cumulative Financing Volume (EURm)




Subsectors




Indications¹



Top Company Origins



Top Investor Origins



Top 5 Deals

#	Company	HQ	Deal Volume	Series
1	YgEia3	UK	683	E
2	Distalmotion	Switzerland	138	F
3	Amolyt Pharma	France	130	C
4	Hemab Therapeutics	Denmark	125	B
5	Ascend Gene And Cell Therapies	UK	120	A

Top 5 Investors

#	Investor	HQ	Deal Volume ²	# of Deals
1	Revival Healthcare Capital	USA	138	1
2	Gilde Healthcare Partners	Denmark	70	5
3	European Innovation Council Fund	Germany	68	16
4	Novo Holdings	Denmark	64	5
5	Jeito	Denmark	61	4

#	Date	Company	HQ	Subsector	Vertical - Indication / Stage	Company Description	Series	Deal Volume (EURm)	Total Raised (EURm)	Deal Synopsis
17	23-05-2023	Mag4health	FRA	MedTech	Medical Device / Developing	Developer of brain imaging systems designed to effectively detect brain defects and improve brain care.	B	5	7	The company raised EUR 5.3 million of venture funding on May 23, 2023.
18	23-05-2023	UTI-lizer	SWE	MedTech	Medical Device / Developing	Developer of point-of-care diagnostic tests designed for urinary tract infections.	A	3	3	The company raised \$3 million of venture funding on May 23, 2023. The funds will be used to set up a commercial production process for the test strips, conduct a clinical study before CE marking and intensify business development work to reach the market.
19	23-05-2023	PhenUtest Diagnostics	GBR	MedTech	Diagnostic Device / Undisclosed	Operator of a diagnostic company focused on the diagnosis and treatment of urinary tract infections.	A	1	1	The company raised GBP 1.17 million of venture funding on May 23, 2023, putting the company's pre-money valuation at GBP 6.06 million.
20	22-05-2023	Patient21	DEU	HealthTech	Healthcare Platform / On market	Operator of a health platform intended to use technology to fix the disjointed healthcare system that many patients and doctors face.	C	100	128	The company raised EUR 100 million of Series C venture funding through a combination of debt and equity on May 22, 2023. The funds will be used for plans to grow its software and expand beyond Germany, the company expects to launch in two new European markets within the next 12 months.
21	22-05-2023	Debx Medical	NLD	Biotech / Pharma	Dermatology / On market	Operator of a medical technology company intended to improve the quality of life of people suffering from chronic wounds.	B	10	10	The company raised EUR 10 million of venture funding on May 22, 2023.
22	22-05-2023	PharmEnable	GBR	Biotech / Pharma	Other / Developing	Operator of a drug discovery company intended to replicate the specificity of biologics in the form of small molecule drugs.	B	7	14	The company raised GBP 6 million of venture funding on May 22, 2023. The funds will be used to advance and expand the company's portfolio of wholly owned and co-discovery projects across oncology and neurology targets, as well as support further platform R&D.
23	18-05-2023	Cyted	GBR	Biotech / Pharma	Oncology / Undisclosed	Developer of a digital diagnostic infrastructure platform designed to detect the early stages of cancer.	B	15	22	The company raised GBP 13.4 million of venture funding on May 18, 2023. The funds will be used to scale in existing markets, as well as entering the US market, and further develop the company's research and development programs across gastrointestinal cancers and diseases and support the expansion work providing early detection tests for oesophageal cancer to NHS patients in primary and community care settings.
24	18-05-2023	Inflection Biosciences	IRL	Biotech / Pharma	Oncology / Pre-clinic	Developer of small molecule therapeutics intended to help in the treatment of cancer.	D	< 1	3	The company raised EUR 518,926 of venture funding on May 18, 2023, putting the company's pre-money valuation at EUR 4.84 million.


Source: PitchBook as of 02-06-2023; FCF Equity Research

Note: All volumes in EURm; financing rounds without deal values are excluded


¹Only includes biotechnology and pharmaceutical deals; ²Proportional attribution of deal values to investors participating in a transaction (transaction volume / # investors by financing round)

Overview (YTD)


Cumulative Financing Volume (EURm)




Subsectors




Indications¹



Top Company Origins



Top Investor Origins



Top 5 Deals

#	Company	HQ	Deal Volume	Series
1	YgEia3		683	E
2	Distalmotion		138	F
3	Amolyt Pharma		130	C
4	Hemab Therapeutics		125	B
5	Ascend Gene And Cell Therapies		120	A

Top 5 Investors

#	Investor	HQ	Deal Volume ²	# of Deals
1	Revival Healthcare Capital		138	1
2	Gilde Healthcare Partners		70	5
3	European Innovation Council Fund		68	16
4	Novo Holdings		64	5
5	Jeito		61	4

#	Date	Company	HQ	Subsector	Vertical - Indication / Stage	Company Description	Series	Deal Volume (EURm)	Total Raised (EURm)	Deal Synopsis
25	17-05-2023	Moon Surgical	FRA	MedTech	Surgical Device / Undisclosed	Developer of surgical devices designed to facilitate access to minimally invasive surgery techniques and optimize operating room resources.	B	50	86	The company raised \$55.4 million of venture funding on May 17, 2023. The funds will be used to accelerate the marketing of the Maestro system.
26	17-05-2023	Halo Therapeutics	GBR	Biotech / Pharma	Infectious Diseases / Pre-clinic	Developer of a pan-coronavirus antivirals designed for the treatment of the Covid-19 virus.	A	2	2	The company raised GBP 1.52 million of venture funding on May 17, 2023, putting the company's pre-money valuation at GBP 2.52 million.
27	16-05-2023	EarSwitch	GBR	MedTech	Medical Device / Developing	Developer of medical devices designed to assist neurologically impaired patients.	A	< 1	< 1	The company raised an estimated GBP 500,000 of venture funding on May 16, 2023. The funds will be used to integrate, test, and trial EarMetrics in industry-standard hearing aids.
28	15-05-2023	Dualyx	BEL	Biotech / Pharma	Immunology / Pre-clinic	Developer of immune modulators designed to provide a cure for autoimmune diseases.	A	40	47	The company raised EUR 40 million of Series A venture funding on May 15, 2023. The funds will be used to progress the company's lead autoimmune program DT-001, as well as its pipeline of Treg candidates.
29	15-05-2023	ScubaTx	GBR	MedTech	Organ Preservation Device / On market	Developer of an organ preservation system designed to commercialize a proven organ preservation technique.	B	2	2	The company raised GBP 1.5 million of venture funding on May 15, 2023. The funds will be used to enhance the company's designs and develop its device, as it looks to obtain the permissions to sell its products worldwide, with a specific focus on the UK, USA, and mainland Europe and an initial eye on pancreatic procedures for patients with diabetes.
30	15-05-2023	Rosa Biotech	GBR	Biotech / Pharma	Other / Developing	Developer of sensing platform designed to provide outcome-focused biosensing for early disease diagnosis and for use in industrial biotechnology.	A	< 1	1	The company raised GBP 415,000 of angel funding on May 15, 2023.
31	11-05-2023	NewBiologix	CHE	Biotech / Pharma	Other / Developing	Developer of a DNA integration platform designed for the advanced engineering of cell lines used in gene and cell therapies.	A	45	45	The company raised \$50 million of series A venture funding on May 11, 2023. The fund will be used for manufacturing of gene and cell therapies.
32	11-05-2023	Capitainer	SWE	MedTech	Blood Testing Device / On market	Developer of a medical device designed to reduce the need to travel and healthcare resources spent on taking blood samples.	C	5	14	The company raised \$ 5.7 million of venture funding on May 11, 2023. The funds will be used to increase production capacity, develop new products, and intensify sales and marketing efforts.


Source: PitchBook as of 02-06-2023; FCF Equity Research

Note: All volumes in EURm; financing rounds without deal values are excluded


¹Only includes biotechnology and pharmaceutical deals; ²Proportional attribution of deal values to investors participating in a transaction (transaction volume / # investors by financing round)

Overview (YTD)


Cumulative Financing Volume (EURm)




Subsectors




Indications¹



Top Company Origins



Top Investor Origins



Top 5 Deals

#	Company	HQ	Deal Volume	Series
1	YgEia3	UK	683	E
2	Distalmotion	Switzerland	138	F
3	Amolyt Pharma	France	130	C
4	Hemab Therapeutics	Denmark	125	B
5	Ascend Gene And Cell Therapies	UK	120	A

Top 5 Investors

#	Investor	HQ	Deal Volume ²	# of Deals
1	Revival Healthcare Capital	USA	138	1
2	Gilde Healthcare Partners	Denmark	70	5
3	European Innovation Council Fund	Germany	68	16
4	Novo Holdings	Denmark	64	5
5	Jeito	Denmark	61	4

#	Date	Company	HQ	Subsector	Vertical - Indication / Stage	Company Description	Deal Series	Deal Volume (EURm)	Total Raised (EURm)	Deal Synopsis
33	11-05-2023	IbisVision	GBR	HealthTech	Health Software / On market	Developer of vision testing software designed to build resilience in the provision of eye care.	G	5	13	The company raised GBP 4.5 million of venture funding on May 11, 2023. The funds will be used to double its workforce and open an office in Fort Lauderdale, Florida.
34	10-05-2023	Diogenx	FRA	Biotech / Pharma	Metabolic Disorders / Pre-clinic	Developer of therapeutic services intended to serve diabetic patients.	A	28	32	The company raised EUR 27.5 million of Series A venture funding on May 10, 2023. The funds will be used to advance the lead drug candidate into clinical development in patients with Type 1 Diabetes (T1D).
35	10-05-2023	Allegro	BEL	Biotech / Pharma	Musculoskeletal Disorders / Developing	Operator of a life science company intended to design, develop and commercialize products at the intersection of biotech and nanotech.	-	6	6	The company raised EUR 5.5 million of venture funding on May 10, 2023. The funds will be used to complete the pre-clinical and first-in-human phases of the company's breakthrough treatment for osteoarthritis.
36	10-05-2023	Delta Diagnostics	NLD	MedTech	Biosensor Technology / Developing	Developer of photonic biosensor technology designed to provide multiplexed biosensing.	A	5	5	The company raised EUR 5.25 million of Series A venture funding on May 10, 2023. The funds will be used to fuel the company's ambitious vision to make fast, sensitive and low-cost biosensors accessible to everyone, transforming the Life Sciences industry and paving the way for new and faster solutions in Life Sciences research.
37	10-05-2023	Backhug	GBR	MedTech	Spine Massage Device / On market	Developer of a spine massage device designed to improve back flexibility and change family life for the better.	B	1	3	The company raised GBP 1.08 million of venture funding on May 10, 2023, putting the company's pre-money valuation at GBP 4.93 million.
38	09-05-2023	Smart4 Diagnostics	DEU	HealthTech	Monitoring Platform / On market	Developer of a real-time monitoring platform designed to ensure the quality of blood samples.	B	4	6	The company raised EUR 3.6 million of venture funding in the form of convertible debt on May 9, 2023. The funds will be used by the company to scale its digital pre-analytical monitoring system within Europe and globally.
39	09-05-2023	Simango	FRA	HealthTech	VR Health Training / On market	Operator of a virtual reality health training platform intended to train hospital staff.	C	4	5	The company raised EUR 3.5 million of venture funding on May 9, 2023. The funds will be used to accelerate the company's growth.
40	09-05-2023	Adamas Biotech	ITA	Biotech / Pharma	Oncology / Phase II	Developer of pharmaceutical products intended to improve the health and well-being of people.	A	< 1	< 1	The company raised EUR 470,000 of venture funding through a combination of debt and equity funding on May 9, 2023. The funds will be used to further accelerate the growth path of Adamas Biotech through the industrial scale-up of the production of Teaphenon E, necessary for the market introduction of the products in the company's pipeline, as well as for the development of new patents, including on diabetic heart disease.


Source: PitchBook as of 02-06-2023; FCF Equity Research

Note: All volumes in EURm; financing rounds without deal values are excluded


¹Only includes biotechnology and pharmaceutical deals; ²Proportional attribution of deal values to investors participating in a transaction (transaction volume / # investors by financing round)

Overview (YTD)


Cumulative Financing Volume (EURm)




Subsectors




Indications¹



Top Company Origins



Top Investor Origins



Top 5 Deals

#	Company	HQ	Deal Volume	Series
1	YgEia3		683	E
2	Distalmotion		138	F
3	Amolyt Pharma		130	C
4	Hemab Therapeutics		125	B
5	Ascend Gene And Cell Therapies		120	A

Top 5 Investors

#	Investor	HQ	Deal Volume ²	# of Deals
1	Revival Healthcare Capital		138	1
2	Gilde Healthcare Partners		70	5
3	European Innovation Council Fund		68	16
4	Novo Holdings		64	5
5	Jeito		61	4

#	Date	Company	HQ	Subsector	Vertical - Indication / Stage	Company Description	Series	Deal Volume (EURm)	Total Raised (EURm)	Deal Synopsis
41	09-05-2023	Lentitek	GBR	Biotech / Pharma	Oncology / Undisclosed	Developer of gene therapies and gene-modified cell therapies designed to help treat cancer patients and to increase lentiviral production yields.	-	< 1	< 1	The company raised GBP 267,575 of angel funding on May 9, 2023, putting the company's pre-money valuation at GBP 1.3 million.
42	08-05-2023	Ascend Gene And Cell Therapies	GBR	Biotech / Pharma	Other / Undisclosed	Operator of a biotechnology firm designed for cell therapy design, development, and manufacturing.	A	120	133	The company raised \$132.5 million of Series A venture funding on May 8, 2023. The funds will be used for the acquisition of CMC capabilities and technologies from Freeline Therapeutics and provides operational resources to build the business.
43	08-05-2023	Amara Therapeutics	IRL	HealthTech	Digital Therapeutic Platform / Developing	Developer of a digital therapeutic platform designed for women to take care of their pelvic health.	A	3	3	The company raised EUR 3 million of venture funding on May 8, 2023. The funds will be used to help further develop its bladder health technology.
44	05-05-2023	NanOptima	GBR	Biotech / Pharma	Ophthalmology / Undisclosed	Developer of ophthalmic drug delivery technology designed to revolutionize ocular drug delivery.	A	< 1	2	The company raised GBP 862,837 of angel funding on May 5, 2023, putting the company's pre-money valuation at GBP 6.50 million.
45	05-05-2023	Dem DX	GBR	HealthTech	Medical Application / On market	Developer of a medical diagnostic application designed to teach medical practitioners better diagnostic skills.	-	< 1	3	The company raised GBP 688,809 of angel funding on May 5, 2023, putting the company's pre-money valuation at GBP 3.10 million.
46	04-05-2023	DomoHealth	CHE	HealthTech	Digital Health Platform / On Market	Developer of innovative digital health platform that connects patients to their local care environment.	C	9	11	The company raised CHF 8.5 million of venture funding on May 4, 2023. The funds will be used to expand the company's business reach across Europe.
47	04-05-2023	Glyconics	GBR	MedTech	Medical Diagnostic Device / Undisclosed	Developer of medical diagnostics device designed for early detection of exacerbation.	B	2	5	The company raised GBP 1.82 million of venture funding on May 4, 2023, putting the company's pre-money valuation at GBP 5.13 million.
48	03-05-2023	Arthex Biotech	ESP	Biotech / Pharma	Musculoskeletal Disorders / Pre-clinic	Developer of anti-microRNAs designed for the treatment of diseases with unmet needs.	B	42	49	The company raised EUR 42 million of Series B venture funding on May 3, 2023. The funds will be used to advance lead compound, ATX-01, an anti-miR designed to target microRNA 23b.


Source: PitchBook as of 02-06-2023; FCF Equity Research

Note: All volumes in EURm; financing rounds without deal values are excluded


¹Only includes biotechnology and pharmaceutical deals; ²Proportional attribution of deal values to investors participating in a transaction (transaction volume / # investors by financing round)

Overview (YTD)


Cumulative Financing Volume (EURm)




Subsectors




Indications¹



Top Company Origins



Top Investor Origins



Top 5 Deals

#	Company	HQ	Deal Volume	Series
1	YgEia3	UK	683	E
2	Distalmotion	Switzerland	138	F
3	Amolyt Pharma	France	130	C
4	Hemab Therapeutics	Denmark	125	B
5	Ascend Gene And Cell Therapies	UK	120	A

Top 5 Investors

#	Investor	HQ	Deal Volume ²	# of Deals
1	Revival Healthcare Capital	US	138	1
2	Gilde Healthcare Partners	Denmark	70	5
3	European Innovation Council Fund	Germany	68	16
4	Novo Holdings	Denmark	64	5
5	Jeito	Denmark	61	4

#	Date	Company	HQ	Subsector	Vertical - Indication / Stage	Company Description	Series	Deal Volume (EURm)	Total Raised (EURm)	Deal Synopsis
49	03-05-2023	Empros Pharma	SWE	Biotech / Pharma	Metabolic Disorders / Developing	Developer of a therapeutic oral drug designed to treat overweight and obesity.	D	7	11	The company raised SEK 80 million of venture funding on May 3, 2023. The funds will be used to accelerate the development of the obesity drug EMP16, as well as strengthen the team.
50	03-05-2023	HelloBetter	DEU	Healthcare Services	Mental Health Services / On market	Developer of digital therapeutics (DTx) and prescription digital therapeutics (PDTx) platforms designed for mental health.	2	6	19	The company raised \$7 million of Series A2 venture funding on May 3, 2023.
51	03-05-2023	AutonoMe	GBR	Healthcare Services	Health Services / On market	Operator of a technology company intended to support people with neurodiversity and learning disabilities with its unique blended support approach.	C	< 1	1	The company raised GBP 300,000 of venture funding on May 3, 2023. The funds will be used to offer support to far more people as well as expand its platform and develop new features making it even more accessible and user-friendly.
52	02-05-2023	Biolytica	CHE	HealthTech	Health Data Management Platform / On market	Developer of AI-based patient health data management platform designed to increase healthspan and performance state-of-the-art through health data analytics.	B	5	11	The company raised CHF 5.34 million of venture funding on May 2, 2023. The funds will be used to fuel growth.
53	02-05-2023	Maddie	FRA	HealthTech	Healthcare Management Platform / Undisclosed	Operator of the healthcare platform intended to help health professionals manage their practices effectively.	A	1	1	The company raised \$1.1 million of venture funding on May 2, 2023. The funds will be used to support paramedics in private practice.
54	01-05-2023	YgEia3	GBR	Healthcare Services	B2B Health Program / On market	Provider of wellness testing program intended to offer customized services based on needs and goals.	E	683	1,163	The company raised \$750 million of venture funding in May 2023.
55	01-05-2023	LS CancerDiag	FIN	Biotech / Pharma	Oncology / On market	Developer of a predictive cancer diagnostic technology intended to reduce cancer mortality rates.	-	5	7	The company raised EUR 5,401,600 of equity crowdfunding in approximately May 2023.
56	01-05-2023	Neurosoft	CHE	MedTech	Implantable Electrodes / On market	Developer of soft implantable electrodes intended to diagnose and treat neurological diseases by recording or electrically stimulating neural tissues.	B	3	< 1	The company joined an Accelerator in May 2023, and received CHF 2.5 million in funding in the form of grants.


Source: PitchBook as of 02-06-2023; FCF Equity Research

Note: All volumes in EURm; financing rounds without deal values are excluded


¹Only includes biotechnology and pharmaceutical deals; ²Proportional attribution of deal values to investors participating in a transaction (transaction volume / # investors by financing round)

Overview (YTD)


Cumulative Financing Volume (EURm)




Subsectors




Indications¹



Top Company Origins



Top Investor Origins



Top 5 Deals

#	Company	HQ	Deal Volume	Series
1	YgEia3	UK	683	E
2	Distalmotion	Switzerland	138	F
3	Amolyt Pharma	France	130	C
4	Hemab Therapeutics	Denmark	125	B
5	Ascend Gene And Cell Therapies	UK	120	A

Top 5 Investors

#	Investor	HQ	Deal Volume ²	# of Deals
1	Revival Healthcare Capital	USA	138	1
2	Gilde Healthcare Partners	Denmark	70	5
3	European Innovation Council Fund	Germany	68	16
4	Novo Holdings	Denmark	64	5
5	Jeito	Denmark	61	4

#	Date	Company	HQ	Subsector	Vertical - Indication / Stage	Company Description	Series	Deal Volume (EURm)	Total Raised (EURm)	Deal Synopsis
57	01-05-2023	Tada Group	SWE	MedTech	Therapy Device / On market	Developer of an intravenous (IV) therapy device designed to provide need-based solutions for the healthcare sector.	B	< 1	5	The company raised EUR 990,000 of venture funding in the form of convertible debt on May 1, 2023.
58	01-05-2023	ACT Medical	GBR	MedTech	Emergency Device / Undisclosed	Operator of a medical technology company intended to revolutionize the standard of care for penetrative trauma and reduce the mortality rates associated with violent crime.	-	< 1	< 1	The company raised GBP 254,991 of angel funding on May 1, 2023, putting the company's pre-money valuation at GBP 2.7 million.
59	01-05-2023	Vitadio	CZE	HealthTech	Medical Platform / On Market	Developer of a medical platform intended to offer clinically-validated digital therapeutics for type 2 diabetes.	-	< 1	< 1	The company joined an Accelerator in approximately May and received EUR 20,000 in the form of convertible notes.

Source: PitchBook as of 02-06-2023; FCF Equity Research

Note: All volumes in EURm; financing rounds without deal values are excluded

¹Only includes biotechnology and pharmaceutical deals; ²Proportional attribution of deal values to investors participating in a transaction (transaction volume / # investors by financing round)

Contact Details & Disclaimer



FCF Fox Corporate Finance GmbH

Maximilianstrasse 12-14 ▪ 80539 Munich ▪ Germany
Telephone +49 (89) 206 0409-0 ▪ Facsimile +49 (89) 206 0409-299
info@fcf.de ▪ www.fcf.de

Arno Fuchs

Chief Executive Officer

P: +49 (89) 206 0409-100
M: +49 (172) 863 6777
arno.fuchs@fcf.de

Mathias Klozenbuecher

Managing Director

P: +49 (89) 2060 409-123
M: +49 (174) 301 1846
mathias.klozenbuecher@fcf.de

Johannes Link

Analyst

P: +49 (89) 206 0409-150
M: +49 (172) 839 5746
johannes.link@fcf.de

Marcel Louis Christou

Junior Analyst

P: +49 (89) 206 0409-127
marcellouis.christou@fcf.de

DISCLAIMER

This document does not constitute an offer or invitation to purchase or subscribe for any securities, and neither this document nor anything contained herein shall form the basis of or may be relied upon in connection with any contract or commitment whatsoever. No representation or warranty (express or implied) is made as to, and no reliance should be placed on, any information, including projections, estimates, targets and opinions, contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and, accordingly, neither FCF nor any of its officers, directors or employees accepts any liability whatsoever arising directly or indirectly from the use of this document. By accepting this document you acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the Company's business. This document contains certain forward-looking statements, including assumptions, opinions and views cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or performance of the Company to differ materially from the estimations expressed or implied herein. FCF does not guarantee that the figures, assumptions and calculations underlying such historical and forward looking statements are free from errors nor does FCF accept any responsibility for the future accuracy of the opinions expressed in this document or the actual occurrence of the forecasted developments.

© FCF Fox Corporate Finance GmbH 2023



THE FINANCING SPECIALIST